S

SuppreMol

Biotech & Life Sciences · Planegg, Germany · Founded 2002

SuppreMol GmbH was a German biopharmaceutical company focused on developing novel protein- and antibody-based therapeutics for autoimmune and allergic diseases. The company originated as a spin-off in 2002 from the laboratory of Nobel Prize Laureate Dr. Robert Huber at the Max Planck Institute for Biochemistry. This foundation provided a strong scientific underpinning, rooted in the structural biology of immune system components. The company's core strategy revolved around modulating Fc receptor signaling pathways, critical checkpoints in the immune response. Its business model was centered on the research and development of a pipeline of drug candidates, with the ultimate goal of commercialization through partnerships or acquisition. SuppreMol's main asset was its pioneering work on soluble Fc-gamma receptor IIB (sFcγRIIB), a recombinant protein designed to regulate the immune system. The lead candidate, SM101, is a soluble, non-glycosylated version of the FcγRIIb receptor. This therapeutic works by binding to autoantibody-autoantigen complexes, which prevents them from activating immune cells and initiating an inflammatory cascade. By downregulating this immune response, SM101 showed potential for treating various autoimmune conditions. The product completed Phase 2a clinical studies for idiopathic thrombocytopenic purpura (ITP) and systemic lupus erythematosus (SLE). The company's pipeline also included other technologies with potential applications in IgE-mediated allergic diseases. After successfully raising capital from investors including MIG Fonds, Santo Holding GmbH, and BioMedInvest AG, and advancing its lead candidate through mid-stage clinical trials, SuppreMol positioned itself as an attractive acquisition target. In March 2015, Baxter International acquired SuppreMol for a total of €200 million (approximately $225 million). The acquisition included SuppreMol's entire development portfolio and its operations in Munich, which were integrated into Baxter's BioScience division to expand its immunology pipeline. Keywords: autoimmune diseases, immunoregulatory therapeutics, Fc receptor signaling, biopharmaceutical, Baxter acquisition, SM101, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, soluble Fc-gamma receptor IIB, protein therapeutics, antibody development, clinical trials, Max Planck Institute spin-off, Robert Huber, Klaus Schollmeier, Peter Buckel, allergy treatment, immunology, Martinsried, sFcγRIIB